FDA Approves Once-Weekly Product for Hemophilia A
The new product, efanesoctocog alfa (Altuviiio), is a long-acting factor VIII replacement that needs to be given only once weekly.
Source: medscape.com
Page 11 - Factor Viii News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Factor Viii. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Factor Viii Today - Breaking & Trending Today
Hemophilia A Gene Therapy Durable at 2 Years; Under FDA Review
Despite an anticipated price tag of $2.5 million, there's no way to predict who will have long-standing benefit from valoctocogene roxaparvovec and who will not.
Source: medscape.com
Global Hemophilia Market Report 2023: Increased Focus on
Dublin, Feb. 22, 2023 (GLOBE NEWSWIRE) -- The "Global Hemophilia Market (By Treatment Regimen, Type & Therapy): Insights & Forecast with...
Source: globenewswire.com
Efanesoctocog Alfa Treatment 'Victory' for Hemophilia A Patients
A once-weekly prophylactic treatment of this investigational agent led to normal or near-normal factor VIII activity levels in most patients with severe hemophilia A.
Source: medscape.com
NHLBI project to study the causes of inhibitor formation in children with Hemophilia A
RTI International is partnering with researchers from the University of Washington and Emory University in the seven-year cooperative agreement.
Source: pressreleasepoint.com